



SIMPLICITY OF **ONE** RECOMMENDED TREATMENT DURATION^{1,2}

**1 ONE PILL.
ONCE DAILY.
ONE DURATION.**

12 weeks. With or without food.¹

No dosage adjustments are possible with EPCLUSA. Please consult the Product Monograph for complete dosing instructions, including ribavirin dosing for patients with decompensated cirrhosis.

EPCLUSA (sofosbuvir/velpatasvir) is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis.¹ Please consult the Product Monograph at: http://www.gilead.ca/application/files/6915/8040/6025/Epclusa_English_PM_e186388-GS-006.pdf for important information relating to contraindications, warnings, adverse reactions, interactions, and dosing. The Product Monograph is also available by calling Gilead at 1-866-207-4267.



1. EPCLUSA (sofosbuvir/velpatasvir) Product Monograph. Gilead Sciences Canada, Inc. January 15, 2020.
2. Data on File. Letter from Gilead Medical, November 28, 2018.

EPCLUSA is a registered trademark of Gilead Sciences, Inc. or its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.